Our Board of Directors
WCCT is a focused specialty contract research organization that has positioned itself for growth since day one. Our agile, innovative and collaborative approach has allowed us to become leaders in various study and therapeutic areas such as ethnobridging, oncology and influenza challenge research.
Our board comes from various backgrounds in healthcare, biotechnology, pharmaceutical, clinical research and business industries. They provide operational oversight and guidance for WCCT, ensuring that the company adapts to the growing landscape of clinical research and is able to provide top-tier service to its clients.
Over the past 20 years, Mr. Craig Albright has been both an operating executive and active in the healthcare private equity community across multiple sectors in healthcare services and IT. Albright is currently EVP at Healogics, Inc., the U.S.’s largest provider of wound care services with over 750 locations. In addition to WCCT, his other board roles have included U.S. HealthWorks, Inc., until its sale to Dignity Health, and Free & Clear, until its sale to Inverness Medical/Alere.
Among his operating leadership roles, he served as CEO of Free & Clear, Inc., and Gentiae Clinical Research. As a senior executive at Vivra Specialty Partners, he oversaw the site management and clinical research businesses. He has also served as strategic advisor to the Cleveland Clinic Foundation and CardioNet, Inc., and served in a voluntary capacity as an advisor to UCSF and Mission Bay Capital, its internal incubator fund.
Albright graduated from Stanford University with a degree in economics, with honors, and earned an MBA from the Stanford Graduate School of Business.
Residing in Hong Kong, Mr. Billy Cho currently serves as a director in Citigroup’s Global Healthcare Investment Banking team, where he is responsible for healthcare client coverage across the Asia-Pacific region with a focus on China, South Korea and Southeast Asia. He has nearly 15 years of professional experience exclusively in healthcare, including 10 years in investment banking based in New York and Hong Kong.
Mr. Cho has facilitated numerous strategic and capital markets transactions on behalf of many global and regional healthcare companies based in the U.S. and across the Asia-Pacific region. He has spoken at numerous healthcare conferences covering a variety of topics ranging from biopharma innovation to M&A/capital markets trends. Mr. Cho was previously with Comprehensive NeuroScience in strategy and operations, and Ernst & Young as an auditor focused on California-based healthcare companies.
Mr. Cho was born in Korea and raised in California, and received his BS from the University of Southern California, MS from the University of Virginia, and MBA from the Wharton School of the University of Pennsylvania.
Gregory P. Hanson
Gregory P. Hanson CMA, MBA, is Chief Financial Officer for MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a position he has held since February 2014. Mr. Hanson is also the Managing Director of First Cornerstone, a board and management advisory service to companies and executives in the areas of international corporate development, financing strategies, commercialization of technologies and products, and M&A advisory service, a position he has held since 2008. Mr. Hanson has over 30 years of experience as CFO, investment banker, and executive business strategist, having structured financing terms and raised over $1 Billion in capital of various forms in the life sciences, high tech and clean tech industries. Mr. Hanson has been the financial executive responsible for successfully leading the efforts to list three companies on U.S. national market exchanges: two on the Nasdaq Stock Market, and one on the NYSE MKT LLC, and completing a reverse merger into a public company. From 2009 to 2016, Mr. Hanson served as Advisory Board Member of Menon International, Inc., a company engaged in development, marketing and sales of biosensor devices and assays, and renewable products, requiring travel to Hong Kong, Singapore, and Malaysia. From 2011 to 2016, Mr. Hanson served on the Life Sciences Advisory Board of Brinson Patrick Securities, a boutique investment bank. Mr. Hanson is Past-President and continuing 10-year Member of the Board of Directors of San Diego Financial Executives International (SDFEI), and a member of the Capital Formation Committee at BIOCOM since 2011. Earlier in his career Mr. Hanson served as Senior VP of Brinson Patrick Securities, where he opened up the San Diego, California branch and introduced at-the-market financing strategies to public life sciences companies. Prior to Brinson Patrick Securities, Mr. Hanson served as Senior VP and CFO of Mast Therapeutics (MSTX—NYSE MKT), and prior to Mast Therapeutics was Vice President and CFO, Chief Accounting Officer, Compliance Officer and Corporate Secretary of Avanir Pharmaceuticals, Inc. (acquired by Otsuka Holdings Co., Ltd.), the developer of the cold sore product Abreva™, and Neudexta™, for the treatment of Pseudobulbar Affect, a central nervous system disorder. Mr. Hanson was a founding and 6-year member of the Small Business Advisory Committee to the U.S. Financial Accounting Standards Board (FASB), and has spoken at various national conferences, industry organizations and panels on financing strategy and mergers and acquisitions, and twice spoken to the U.S. Securities and Exchange Commission’s Committee on Improvements to Financial Reporting. Mr. Hanson has passed the examination for Certified Public Accountants and is a Certified Management Accountant. He has a Master’s in Business Administration (MBA) with distinction from the University of Michigan, and a Bachelor of Science (BS) in Mechanical Engineering from Kansas State University. From 2008 to 2016 Mr. Hanson maintained Series 7 & Series 63 securities licenses in the U.S.
Mark G. Hilderbrand
Mr. Mark Hilderbrand has been a managing director at Housatonic Partners since 2006 and has more than 16 years of experience in private equity. Prior to Housatonic, he was a general partner at Onset Ventures and worked at Summit Partners, where he focused on recapitalizations and buyouts of high-growth technology and services businesses. Earlier in his career, he worked as a management consultant at Bain & Company. Mr. Hilderbrand holds a BS from Boston University, an MS from Stanford University, and an MBA from the Harvard Business School. He led the firm’s investment in exponential media and is a director of Learner’s Digest International, LLC; Onrad, Inc; Onsite Health, Inc; QMC International, LLC; WCCT; and the Harvard Business School Alumni Association of Northern California.
Kenneth T. Kim
Dr. Kenneth Kim, a summa cum laude graduate of Harvard College, received his MD from Harvard Medical School. Following a fellowship at the MIT Sloan School of Management, he completed his internal medicine and allergy/immunology training at UCLA. Dr. Kim has served as a medical monitor, consultant or investigator on over 500 clinical trials, having published over 30 research articles and 50 abstracts in peer-reviewed journals. He has presented to the FDA on challenges and strategies of dose selection and study design for pediatric trials and met key decision makers at the PMDA, SFDA, and KFDA. He has spoken at multiple national and international meetings and is a well-recognized expert in the areas of clinical pharmacology, ethnobridging, and respiratory and allergic diseases. He is the founder and Chief Medical Officer of WCCT.
Paul H. Kim
Mr. Paul Kim has over 20 years of professional experience in R&D and business management in the bio industry. He started his career in 1994 at Genentech, a global leader in biotechnology. Before founding Medivate, Mr. Kim served as the head of Novartis Venture Fund Korea (NVFK), the first global pharmaceutical fund to focus solely on innovative Korean biotech investments. Most recently, Mr. Kim served as co-founder and head of POSCO BioVentures, a $62M venture fund focused on U.S. and EU biotech investments on behalf of POSCO, a $40B steel conglomerate. Mr. Kim also served as the vice president of business development at ViroMed (KOSDAQ: 084990), a leading public biotherapeutics company, overseeing the company’s corporate development activities. Prior to ViroMed, Mr. Kim served as vice president at CrystalGenomics (KOSDAQ 083790), forging key strategic partnerships during his tenure. Mr. Kim received his bachelor’s degree in molecular cell biology from UC Berkeley, and is a graduate of the Life Sciences Executive program. Currently, Mr. Kim is a member of the National Venture Capital Association (NVCA) and Bio chapter member of the Licensing Executives Society International (LESI).
Mr. Bill Taaffe retired from ICON Clinical Research in June 2011 after 40 years’ experience within the pharmaceutical and CRO industry. He was one of the founding members of ICON, where he held the position of president and chief executive officer, North America. He was with ICON for 18 years. Prior to that, he spent two years with a generic pharma company, Circa Pharmaceuticals, two years with a preclinical research organization, Bioresearch, and 18 years with a global CRO, the Institute of Clinical Pharmacology, where he served as U.S. CEO. He holds a B.Sc. from University College Dublin, Ireland. He now lives in Tennessee.